<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="11084"><DrugName>gemifloxacin (oral), Il Dong/ Pfizer/ Vansen/LG Life Sciences</DrugName><DrugNamesKey><Name id="42776354">Factive</Name><Name id="42749206">gemifloxacin</Name><Name id="42749209">gemifloxacin mesylate</Name></DrugNamesKey><DrugSynonyms><Name><Value>gemifloxacin</Value><Types><Type>INN</Type></Types></Name><Name><Value>LB-20304</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>SB-265805</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>gemifloxacin mesylate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>LB-20304a</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>SB 265805S</Value></Name><Name><Value>Factive</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>gemifloxacin (oral), LG life Sciences/Oscient</Value></Name><Name><Value>ARB-FV0127</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>gemifloxacin (oral), Oscient/ Abbott/ Il Dong</Value></Name><Name><Value>gemifloxacin (oral), Il Dong/ Pfizer/ Vansen</Value></Name><Name><Value>gemifloxacin (oral), Il Dong/ Pfizer/ Vansen/LG Life Sciences</Value></Name><Name><Value>175463-14-6</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>210353-53-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22235">LG Chem Ltd</CompanyOriginator><CompaniesPrimary><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Company id="13708">Ache Laboratorios Farmaceuticos SA</Company><Company id="30057">LG Life Sciences Ltd</Company><Company id="18767">Pfizer Inc</Company><Company id="1068473">Vansen Pharma Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1043326">Chiesi USA Inc</Company><Company id="1062392">Merus Labs International Inc</Company><Company id="13601">Abbott Laboratories</Company><Company id="15523">Oscient Pharmaceuticals Corp</Company><Company id="18053">The Menarini Group</Company><Company id="19962">SmithKline Beecham plc</Company><Company id="22235">LG Chem Ltd</Company><Company id="24151">SmithKline Beecham Pharmaceuticals [US]</Company><Company id="28023">Genesoft Inc</Company><Company id="28355">GlaxoSmithKline plc</Company><Company id="30124">aRigen Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="11084" type="Drug"><TargetEntity id="226496" type="siDrug">Gemifloxacin mesilate</TargetEntity></SourceEntity><SourceEntity id="1043326" type="Company"><TargetEntity id="4295912989" type="organizationId">RespireRx Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1062392" type="Company"><TargetEntity id="5035527245" type="organizationId">Merus Labs Inc</TargetEntity></SourceEntity><SourceEntity id="1068473" type="Company"><TargetEntity id="5037349898" type="organizationId">Vansen Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="13708" type="Company"><TargetEntity id="4296648672" type="organizationId">Ache Laboratorios Farmaceuticos SA</TargetEntity></SourceEntity><SourceEntity id="15523" type="Company"><TargetEntity id="4295906577" type="organizationId">Oscient Pharmaceuticals Corp</TargetEntity></SourceEntity><SourceEntity id="17101" type="Company"><TargetEntity id="4295881034" type="organizationId">Ildong Holdings Co Ltd</TargetEntity></SourceEntity><SourceEntity id="18053" type="Company"><TargetEntity id="4296446248" type="organizationId">A Menarini Industrie Farmaceutiche Riunite Srl</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="19962" type="Company"><TargetEntity id="5000780276" type="organizationId">Smithkline Beecham Ltd</TargetEntity></SourceEntity><SourceEntity id="22235" type="Company"><TargetEntity id="4295882004" type="organizationId">LG Chem Ltd</TargetEntity></SourceEntity><SourceEntity id="24151" type="Company"><TargetEntity id="5035523851" type="organizationId">Smithkline Beecham Pharmaceuticals Co</TargetEntity></SourceEntity><SourceEntity id="28023" type="Company"><TargetEntity id="5035970709" type="organizationId">Genesoft Inc</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="30057" type="Company"><TargetEntity id="4295882492" type="organizationId">LG Life Sciences Ltd</TargetEntity></SourceEntity><SourceEntity id="30124" type="Company"><TargetEntity id="5035524439" type="organizationId">aRigen Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1061" type="ciIndication"><TargetEntity id="10040753" type="MEDDRA"/><TargetEntity id="D012852" type="MeSH"/><TargetEntity id="-2064751732" type="omicsDisease"/><TargetEntity id="302" type="siCondition"/></SourceEntity><SourceEntity id="1484" type="ciIndication"><TargetEntity id="10060693" type="MEDDRA"/></SourceEntity><SourceEntity id="1798" type="ciIndication"><TargetEntity id="10054088" type="MEDDRA"/></SourceEntity><SourceEntity id="360" type="ciIndication"><TargetEntity id="10035664" type="MEDDRA"/><TargetEntity id="D011014" type="MeSH"/><TargetEntity id="-104071315" type="omicsDisease"/><TargetEntity id="4597" type="siCondition"/></SourceEntity><SourceEntity id="394" type="ciIndication"><TargetEntity id="10033078" type="MEDDRA"/><TargetEntity id="D010033" type="MeSH"/><TargetEntity id="-2113735649" type="omicsDisease"/><TargetEntity id="898" type="siCondition"/></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"/><TargetEntity id="10060945" type="MEDDRA"/><TargetEntity id="D001424" type="MeSH"/><TargetEntity id="-1693440076" type="omicsDisease"/><TargetEntity id="800" type="siCondition"/></SourceEntity><SourceEntity id="431" type="Action"><TargetEntity id="901" type="Mechanism">DNA Gyrase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00623" type="ciTarget"><TargetEntity id="59521" type="siTarget">DNA gyrase (bacterial)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Bacterial respiratory tract infection - South Korea - Jan-2003</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1061">Sinusitis</Indication><Indication id="1484">Bacterial respiratory tract infection</Indication><Indication id="360">Pneumonia</Indication><Indication id="3898">Complicated urinary tract infection</Indication><Indication id="394">Otitis media</Indication><Indication id="40">Bacterial infection</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1798">Bacterial urinary tract infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="431">DNA gyrase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="3984">Bacterial nucleic acid synthesis inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="66">Antibiotic</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-02-21T09:56:58.000Z</LastModificationDate><ChangeDateLast>2019-02-21T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15523" linkType="Company"&gt;&lt;/ulink&gt;Gemifloxacin (Factive; SB-265805, LB-20304a; ARB-FV0127), a fluoronaphthyridone active against both gram-positive and gram-negative bacteria, including methicillin-resistant staphylococci, was originally developed and launched by &lt;ulink linkID="22235" linkType="Company"&gt;LG Chemical&lt;/ulink&gt;. It has since been launched by licensees including &lt;ulink linkID="13601" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="17101" linkType="Company"&gt;Il Dong&lt;/ulink&gt; [&lt;ulink linkID="1443788" linkType="Reference"&gt;1443788&lt;/ulink&gt;], &lt;ulink linkID="18767" linkType="Company"&gt;Pfizer&lt;/ulink&gt; [&lt;ulink linkID="649005" linkType="Reference"&gt;649005&lt;/ulink&gt;], and &lt;ulink linkID="1068473" linkType="Company"&gt;Vansen&lt;/ulink&gt; [&lt;ulink linkID="1469863" linkType="Reference"&gt;1469863&lt;/ulink&gt;]. Gemifloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (AECB), for the 7-day treatment of mild-to-moderate community-acquired pneumonia (CAP) caused by the designated susceptible bacterial strains [&lt;ulink linkID="574751" linkType="Reference"&gt;574751&lt;/ulink&gt;], and otitis media (tympanitis)  [&lt;ulink linkID="1101450" linkType="Reference"&gt;1101450&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2004, &lt;ulink linkID="15523" linkType="Company"&gt;Oscient&lt;/ulink&gt; originally launched  gemifloxacin in the US for the treatment of AECB and mild-to-moderate CAP [&lt;ulink linkID="331765" linkType="Reference"&gt;331765&lt;/ulink&gt;], [&lt;ulink linkID="332458" linkType="Reference"&gt;332458&lt;/ulink&gt;], [&lt;ulink linkID="558496" linkType="Reference"&gt;558496&lt;/ulink&gt;]. In September 2009, &lt;ulink linkID="1043326" linkType="Company"&gt;Cornerstone Therapeutics&lt;/ulink&gt; (now Chiesi) acquired Oscient's rights to the drug  [&lt;ulink linkID="1054480" linkType="Reference"&gt;1054480&lt;/ulink&gt;]; in March 2012, &lt;ulink linkID="1062392" linkType="Company"&gt;Merus Labs International&lt;/ulink&gt; acquired Cornerstone's North American rights, of which the US  marketing rights were also then sublicensed to &lt;ulink linkID="1068473" linkType="Company"&gt;Vansen Pharma&lt;/ulink&gt; [&lt;ulink linkID="1269532" linkType="Reference"&gt;1269532&lt;/ulink&gt;], [&lt;ulink linkID="1269523" linkType="Reference"&gt;1269523&lt;/ulink&gt;];  in August 2013, Okana Ventures (which became Vansen) acquired Merus' North American rights due to strategic reasons [&lt;ulink linkID="1469863" linkType="Reference"&gt;1469863&lt;/ulink&gt;], [&lt;ulink linkID="1471728" linkType="Reference"&gt;1471728&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Oscient filed for label extensions in the US for gemifloxacin as a 5-day treatment for mild-to-moderate CAP and acute bacterial sinusitis (ABS) in November 2005 [&lt;ulink linkID="636322" linkType="Reference"&gt;636322&lt;/ulink&gt;]. In January 2006, the FDA accepted the sNDA for the 5-day treatment of CAP, but refused the sNDA for the 5 -day treatment of ABS, stating that gemifloxacin did not exhibit an acceptable risk-benefit profile, and noting that demonstrating an acceptable profile was unlikely to be feasible because of the potential risk of rash [&lt;ulink linkID="646184" linkType="Reference"&gt;646184&lt;/ulink&gt;].  In September 2006, the agency issued an approvable letter for the 5-day  treatment of  CAP; an FDA advisory panel also recommended against approval of gemifloxacin for ABS as the clinical data submitted  did not demonstrate efficacy as a 5-day treatment  and the risks of the drug outweighed the benefits in this indication  [&lt;ulink linkID="692971" linkType="Reference"&gt;692971&lt;/ulink&gt;], [&lt;ulink linkID="690096" linkType="Reference"&gt;690096&lt;/ulink&gt;]. In May 2007, gemifloxacin was approved by the FDA for the 5-day treatment of CAP [&lt;ulink linkID="789837" linkType="Reference"&gt;789837&lt;/ulink&gt;], [&lt;ulink linkID="812218" linkType="Reference"&gt;812218&lt;/ulink&gt;]. By November 2013, &lt;ulink linkID="30057" linkType="Company"&gt;LG Life Sciences&lt;/ulink&gt; had received approval for the drug in Mexico and South Africa for the treatment of complicated urinary tract infections (cUTI) [&lt;ulink linkID="1497639" linkType="Reference"&gt;1497639&lt;/ulink&gt;]. By April 2015, LG Life Sciences had received approval for the drug for the treatment of CAP, AECB, acute bacterial sinusitis and otitis media in China, and was subsequently the drug was launched in China [&lt;ulink linkID="1653472" linkType="Reference"&gt;1653472&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 1999, an NDA was submitted to the FDA  by &lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt; (GSK) for the treatment of bacterial respiratory and urinary tract infections (RTI/UTI), however, a non-approvable letter was issued in December 2000 [&lt;ulink linkID="393893" linkType="Reference"&gt;393893&lt;/ulink&gt;].  By April 2002, GSK had discontinued development. At that time, LG Chemicals had planned to continue to seek FDA approval [&lt;ulink linkID="447913" linkType="reference"&gt;447913&lt;/ulink&gt;].  In October 2000, phase II trials for bacterial infection were ongoing in Japan, presumed to be by &lt;ulink linkID="30124" linkType="Company"&gt;aRigen Pharmaceuticals&lt;/ulink&gt; [&lt;ulink linkID="384751" linkType="reference"&gt;384751&lt;/ulink&gt;]; however, no further development had been reported by November 2011, and development was presumed to have been discontinued. In May 2008, Oscient's European licensee, &lt;ulink linkID="18053" linkType="Company"&gt;Menarini&lt;/ulink&gt;, made a filing in Europe for CAP, AECB and ABS [&lt;ulink linkID="903511" linkType="Reference"&gt;903511&lt;/ulink&gt;]. However, in June 2009, Menarini withdrew the MAA as the CHMP of the EMEA believed the data was not sufficient to show a positive risk/benefit profile [&lt;ulink linkID="1020645" linkType="Reference"&gt;1020645&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;The product patent for gemifloxacin, &lt;ulink linkID="IN2175712" linkType="Patent"&gt;US-05633262&lt;/ulink&gt;, expires June 15, 2015. However, during 2004, Oscient improved the patent portfolio for gemifloxacin tablets with the receipt of a composition of matter patent, &lt;ulink linkID="PA2902856" linkType="Patent"&gt;US-06723734&lt;/ulink&gt;, with expiration March 20, 2018 [&lt;ulink linkID="587377" linkType="Reference"&gt;587377&lt;/ulink&gt;]. &lt;ulink linkID="PA2902856" linkType="Patent"&gt;US-06723734&lt;/ulink&gt; claims a crystalline form of gemifloxacin mesylate, which is the marketed form of Factive, and is therefore a product derivative patent. According to TS analysts, both patents are constraining, though it is likely that there would be a patent challenge when the earlier patent, &lt;ulink linkID="IN2175712" linkType="Patent"&gt;US-05633262&lt;/ulink&gt;, expires [&lt;ulink linkID="644947" linkType="Reference"&gt;644947&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;Oscient filed for label extensions in the US for gemifloxacin as a 5-day treatment for mild-to-moderate CAP and ABS in November 2005 [&lt;ulink linkID="636322" linkType="Reference"&gt;636322&lt;/ulink&gt;]. In January 2006, the FDA accepted the sNDA for the 5-day treatment of CAP, but refused the sNDA for the 5 -day treatment of ABS, stating that gemifloxacin did not exhibit an acceptable risk-benefit profile, and noting that demonstrating an acceptable profile was unlikely to be feasible because of the potential risk of rash [&lt;ulink linkID="646184" linkType="Reference"&gt;646184&lt;/ulink&gt;].  In September 2006, the agency issued an approvable letter for the 5-day  treatment of  CAP, requesting clarification and additional interpretation regarding certain data included in the application; an FDA advisory panel also recommended against approval of gemifloxacin for ABS as the clinical data submitted  did not demonstrate efficacy as a 5-day treatment  and the risks of the drug outweighed the benefits in this indication  [&lt;ulink linkID="692971" linkType="Reference"&gt;692971&lt;/ulink&gt;], [&lt;ulink linkID="690096" linkType="Reference"&gt;690096&lt;/ulink&gt;]. In May 2007, gemifloxacin was approved by the FDA for the 5-day treatment of CAP [&lt;ulink linkID="789837" linkType="Reference"&gt;789837&lt;/ulink&gt;], [&lt;ulink linkID="812218" linkType="Reference"&gt;812218&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 1999, &lt;ulink linkID="28355" linkType="Company"&gt;GSK&lt;/ulink&gt; submitted an NDA for gemifloxacin for the treatment of bacterial respiratory and urinary tract infections (RTI/UTI), including CAP, chronic bronchitis and ABS [&lt;ulink linkID="350783" linkType="reference"&gt;350783&lt;/ulink&gt;]; however, a non-approvable letter was issued in December 2000 [&lt;ulink linkID="393893" linkType="reference"&gt;393893&lt;/ulink&gt;]. Following this, &lt;ulink linkID="28355" linkType="Company"&gt;GSK&lt;/ulink&gt; was in discussions with the FDA and had expected launch in 2002 [&lt;ulink linkID="399771" linkType="reference"&gt;399771&lt;/ulink&gt;], [&lt;ulink linkID="399788" linkType="reference"&gt;399788&lt;/ulink&gt;], [&lt;ulink linkID="424619" linkType="reference"&gt;424619&lt;/ulink&gt;]; however, by February 2002, launch was no longer expected [&lt;ulink linkID="439764" linkType="reference"&gt;439764&lt;/ulink&gt;], [&lt;ulink linkID="439763" linkType="reference"&gt;439763&lt;/ulink&gt;] and by April 2002, &lt;ulink linkID="28355" linkType="Company"&gt;GSK&lt;/ulink&gt; had discontinued development. At that time, LG Chemicals planned to continue to seek FDA approval [&lt;ulink linkID="447913" linkType="reference"&gt;447913&lt;/ulink&gt;]. In 2002, LG Chemical submitted an NDA to the FDA  [&lt;ulink linkID="476235" linkType="reference"&gt;476235&lt;/ulink&gt;], [&lt;ulink linkID="478433" linkType="reference"&gt;478433&lt;/ulink&gt;]. In March 2003, gemifloxacin was recommended for approval for the treatment of mild-to-moderate CAP and AECB [&lt;ulink linkID="480760" linkType="reference"&gt;480760&lt;/ulink&gt;], [&lt;ulink linkID="483840" linkType="reference"&gt;483840&lt;/ulink&gt;], and in April 2003, the FDA approved gemifloxacin, as Factive, for this indication [&lt;ulink linkID="484780" linkType="reference"&gt;484780&lt;/ulink&gt;]. In July 2003, the FDA approved the sNDA  for gemifloxacin for mild-to-moderate CAP due to multidrug resistant Streptococcus pneumoniae [&lt;ulink linkID="499414" linkType="reference"&gt;499414&lt;/ulink&gt;]. In September 2004, Oscient launched gemifloxacin in the US for both indications [&lt;ulink linkID="558496" linkType="Reference"&gt;558496&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 2004, Oscient was reviewing its strategy for a European filing; at that time it anticipated filing for EU approval in 2006 [&lt;ulink linkID="540819" linkType="reference"&gt;540819&lt;/ulink&gt;].  In May 2008, an EU filing was made [&lt;ulink linkID="903511" linkType="Reference"&gt;903511&lt;/ulink&gt;]. However, in June 2009, Menarini withdrew the MAA as the CHMP of the EMEA believed the data was not sufficient to show a positive risk/benefit profile [&lt;ulink linkID="1020645" linkType="Reference"&gt;1020645&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In March 2004, gemifloxacin was approved in Canada for AECB [&lt;ulink linkID="527068" linkType="reference"&gt;527068&lt;/ulink&gt;].  In March 2007, Oscient's licensee, &lt;ulink linkID="13601" linkType="Company"&gt;Abbott Laboratories&lt;/ulink&gt;, launched the drug for  AECB in Canada [&lt;ulink linkID="770159" linkType="Reference"&gt;770159&lt;/ulink&gt;]. However, the product was removed from the market in February 2009  [&lt;ulink linkID="1471781" linkType="Reference"&gt;1471781&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;In August 2006, gemifloxacin was approved in Mexico for the five-day treatment of  CAP, AECB and ABS [&lt;ulink linkID="681390" linkType="Reference"&gt;681390&lt;/ulink&gt;]; it was launched there by Pfizer in October 2006 for these indications  [&lt;ulink linkID="728581" linkType="Reference"&gt;728581&lt;/ulink&gt;]. By November 2013, LG Life Sciences had received approval for the drug in Mexico for the treatment of (cUTI) [&lt;ulink linkID="1497639" linkType="Reference"&gt;1497639&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2012, the drug had been approved in Brazil by &lt;ulink linkID="13708" linkType="Company"&gt;Ache&lt;/ulink&gt; [&lt;ulink linkID="1647989" linkType="Reference"&gt;1647989&lt;/ulink&gt;]. By November 2017, the drug was launched in Brazil by Ache for bacterial infecions [&lt;ulink linkID="2120389" linkType="Reference"&gt;2120389&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;By November 2013, LG Life Sciences had received approval for the drug in  South Africa for the treatment of complicated urinary tract infections (cUTI) [&lt;ulink linkID="1497639" linkType="Reference"&gt;1497639&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By April 2015, LG Life Sciences had received approval for the drug for the treatment of CAP, AECB, acute bacterial sinusitis and otitis media in China, and was subsequently the drug was launched in China [&lt;ulink linkID="1653472" linkType="Reference"&gt;1653472&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2002, gemifloxacin had been approved in South Korea for [&lt;ulink linkID="490551" linkType="reference"&gt;490551&lt;/ulink&gt;], [&lt;ulink linkID="1101360" linkType="Reference"&gt;1101360&lt;/ulink&gt;]. In February 2006, it was launched in South Korea   [&lt;ulink linkID="683995" linkType="Reference"&gt;683995&lt;/ulink&gt;]. By February 2010, the agent was also approved for otitis media [&lt;ulink linkID="1101450" linkType="Reference"&gt;1101450&lt;/ulink&gt;]; it was presumed that the agent was launched shortly afterwards.   &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In July 2018, the FDA updated the safety labelling for fluoroquinolones, including gemifloxacin, regarding mental health side effects and serious blood sugar disturbances; the mental health side effects to include are disturbances in attention, disorientation, agitation, nervousness, memory impairment and delirium. The Blood Glucose Disturbances label subsection  is now required to explicitly reflect the potential risk of coma with hypoglycemia [&lt;ulink linkID="2052785" linkType="Reference"&gt;2052785&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;Initiated in 2004, as a post-marketing commitment to the FDA, the 7500 patient, phase IV FORCE trial compared gemifloxacin and &lt;ulink linkID="2829" linkType="Drug"&gt;clarithromycin&lt;/ulink&gt;  in CAP and gemifloxacin and &lt;ulink linkID="44284" linkType="Drug"&gt;amoxicillin/clavulanate&lt;/ulink&gt;  in AECB patients. It included populations not substantially represented in the existing program, specifically as it relates to rash [&lt;ulink linkID="553267" linkType="Reference"&gt;553267&lt;/ulink&gt;], [&lt;ulink linkID="549679" linkType="Reference"&gt;549679&lt;/ulink&gt;]. In March 2005, completion was expected within the next three to four years [&lt;ulink linkID="591575" linkType="Reference"&gt;591575&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Acute bacterial exacerbation of chronic bronchitis&lt;/subtitle&gt;One of  two studies published in August 2004 showed an 88.2% clinical success for 5-day once-daily gemifloxacin treatment cf 85.1% for 7-day once-daily &lt;ulink linkID="3492" linkType="Drug"&gt;levofloxacin&lt;/ulink&gt;  in patients with AECB. The clinical success rate at long-term follow-up was 80.8% for gemifloxacin cf 70.8% for levofloxacin. Second study published in CAP patients showed no statistically different clinical success between a 7 days once-daily gemifloxacin treatment and a 10-day, high dose, three times daily &lt;ulink linkID="44284" linkType="Drug"&gt;amoxicillin/clavulanate&lt;/ulink&gt; regimen [&lt;ulink linkID="553974" linkType="Reference"&gt;553974&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2005, clinical data on gemifloxacin were presented at the 45th ICAAC meeting in Washington DC. Pooled data from 10 phase III trials indicated that prior antibiotic therapy did not affect the high success rates of gemifloxacin treatment of AECB [&lt;ulink linkID="641463" linkType="Reference"&gt;641463&lt;/ulink&gt;].  Pooled data from 17 phase III trials supported the use of gemifloxacin against respiratory tract infections as success of treatment was consistently high against all resistance phenotypes including penicillin and macrolide-resistant strains [&lt;ulink linkID="641465" linkType="Reference"&gt;641465&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In treating, AECB in patients with  underlying medical conditions including asthma and sinusitis, the drug was as effective as other treatments such as &lt;ulink linkID="2829" linkType="Drug"&gt;clarithromycin&lt;/ulink&gt;, &lt;ulink linkID="3492" linkType="Drug"&gt;levofloxacin&lt;/ulink&gt;, trovafloxacin and amoxicillin-clavulanate (90% clinical response rate) [&lt;ulink linkID="627590" linkType="Reference"&gt;627590&lt;/ulink&gt;]. In April 2006, similar data were presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases in Nice, France [&lt;ulink linkID="660105" linkType="Reference"&gt;660105&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2004, results were reported from a randomized, double-blind study comparing gemifloxacin with &lt;ulink linkID="3492" linkType="Drug"&gt;levofloxacin&lt;/ulink&gt; in patients with AECB. Results showed clinical success with gemifloxacin 320 mg once-daily for 5 days (88.2%), compared to once-daily dosing of levofloxacin 500 mg for 7 days (85.1%). The clinical success rates at long-term follow-up were 80.8% for gemifloxacin and 70.8% for levofloxacin, a significant difference. Gemifloxacin-treated patients experienced high rates of bacteriological eradication ranging from 75% to 100% [&lt;ulink linkID="554126" linkType="Reference"&gt;554126&lt;/ulink&gt;], [&lt;ulink linkID="553974" linkType="Reference"&gt;553974&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2000, data on gemifloxacin were presented at the 40th ICAAC meeting in Toronto, Canada. Results of a double-blind active-controlled phase III study involving 709 patients revealed the greater efficacy of 5-day treatment with gemifloxacin (320 mg/day) compared to 7-day treatment with &lt;ulink linkID="2829" linkType="Drug"&gt;clarithromycin&lt;/ulink&gt; (500 mg bid) in the treatment of bacterial RTIs associated with chronic bronchitis. In follow-up evaluation at week 5, success rates with gemifloxacin were significantly better than those with clarithromycin, 81.8% and 62.0%, respectively. Additionally, bacterial eradication was faster with gemifloxacin, occurring on day 1 of treatment [&lt;ulink linkID="382663" linkType="reference"&gt;382663&lt;/ulink&gt;]. At 6 months, 30% fewer gemifloxacin-treated patients showed recurrences of AECB requiring antibiotic treatment, compared to the clarithromycin group. By week 26, 71% of patients in the gemifloxacin arm (120 out of 169 patients), versus 59% (100 out of 171 patients) in the clarithromycin arm, had their initial AECB resolved and experienced no further recurrences [&lt;ulink linkID="381886" linkType="reference"&gt;381886&lt;/ulink&gt;], [&lt;ulink linkID="384280" linkType="reference"&gt;384280&lt;/ulink&gt;]. Similar data were presented in March 2004, at the Sixth SMi Superbugs &amp;amp; Superdrugs: A Focus on Antibacterials meeting in London, UK [&lt;ulink linkID="526541" linkType="reference"&gt;526541&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Community-acquired pneumonia&lt;/subtitle&gt;In April 2006, a meta-analysis of six phase III trials showed  a trend toward higher clinical success rates with gemifloxacin versus comparators in patients with CAP with other risk factors [&lt;ulink linkID="660105" linkType="Reference"&gt;660105&lt;/ulink&gt;]. Retrospective phase III analysis from a subset of at-risk patients with CAP and comorbidities, presented in October 2006 at   the 44th Annual Meeting of the Infectious Diseases Society of America, demonstrated  a 90.9% response rate in the 5-day treatment group and a 92.7% response rate in the 5-day group. Gemifloxacin was generally well tolerated with a low incidence of adverse events [&lt;ulink linkID="730990" linkType="Reference"&gt;730990&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004, Oscient initiated preparations for a clinical study to demonstrate that a 5-day course of gemifloxacin  for the treatment of mild-to-moderate CAP was as effective as the  approved 7-day course of treatment.  The double-blind study was to be conducted at up to 100 North American and European sites and  enroll 459 patients. The primary endpoint was the clinical response rate at the follow-up visit, with secondary endpoints of clinical response at end of therapy, radiological response at follow-up and bacteriological response at end of therapy and at follow-up [&lt;ulink linkID="549679" linkType="Reference"&gt;549679&lt;/ulink&gt;].  In March 2005, enrollment of more than 460 patients was completed [&lt;ulink linkID="589060" linkType="Reference"&gt;589060&lt;/ulink&gt;]. In June 2005, results were released. A 5-day dosing regimen of gemifloxacin was non-inferior to the FDA-approved 7-day dosing regimen against community-acquired pneumonia. A label extension would be sought [&lt;ulink linkID="605891" linkType="Reference"&gt;605891&lt;/ulink&gt;]. In September 2005, similar results were presented at the 2nd International Conference on Community-Acquired Pneumonia in Montreal, Canada [&lt;ulink linkID="623625" linkType="Reference"&gt;623625&lt;/ulink&gt;]. In June 2007, similar data were published [&lt;ulink linkID="803928" linkType="Reference"&gt;803928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; In a phase III study in CAP patients, gemifloxacin once-daily for 7 days resulted in a clinical success rate of 88.7%, similar to that reported for high-dose &lt;ulink linkID="44284" linkType="Drug"&gt;amoxicillin/clavulanate&lt;/ulink&gt; give three times a day for 10 days (87.6%). Gemifloxacin also eradicated 95.7% of S pneumoniae clinical isolates, including those resistant to penicillin and macrolides [&lt;ulink linkID="554129" linkType="Reference"&gt;554129&lt;/ulink&gt;], [&lt;ulink linkID="553974" linkType="Reference"&gt;553974&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2001, clinical data on gemifloxacin were presented at the 41st ICAAC meeting in Chicago, IL. This international phase III trial compared gemifloxacin (320 mg/day, n=15) with &lt;ulink linkID="2867" linkType="Drug"&gt;trovafloxacin&lt;/ulink&gt; (200 mg/day, n=3), clinical and laboratory features of 28 cases of Legionella pneumonia. Overall clinical success occurred in 25 (93%) of patients after 7 days of treatment and only one patient required 14 days of treatment. There was one adverse event withdrawal and one clinical failure [&lt;ulink linkID="421316" linkType="reference"&gt;421316&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Acute bacterial sinusitis&lt;/subtitle&gt;In October 2005, Oscient presented a meta-analysis of phase III studies at the 43rd Annual Meeting of the Infectious Diseases Society of America in San Francisco, CA. In treating ABS in allergic rhinitis patients, the drug was more effective than &lt;ulink linkID="44368" linkType="Drug"&gt;cefuroxime&lt;/ulink&gt; and &lt;ulink linkID="2867" linkType="Drug"&gt;trovafloxacin&lt;/ulink&gt; [&lt;ulink linkID="627590" linkType="Reference"&gt;627590&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2004, data from a randomized, double-blind phase III trial in  ABS were presented at the 42nd Annual Meeting of the Infectious Diseases Society of America in Boston, MA. The study assessed the efficacy and safety of once-daily administration of 320 mg gemifloxacin tablets for either 5 or 7 days in a group of 356 patients aged 18 to 80 years. The proportion of patients reaching the primary efficacy endpoint of sufficient improvement or resolution of signs and symptoms at follow-up was 87.3 and 86.9%, at 5 and 7 days treatment with gemifloxacin, respectively. In a further study, bacteriologic and clinical efficacy and safety of gemifloxacin tablets given once daily for 5 days to patients ages 16 to 81 was assessed. In patients treated with the drug, 90.3% of all initial pathogens were eradicated, without any new infections. At follow-up, there was  100%  clinical success and bacteriological eradication rate for penicillin-resistant isolates of S pneumoniae from patients in the study. These results, together with those from two completed comparative head-to-head phase III trials, were expected to form the basis of a regulatory submission to the FDA for ABS in 2005. At that time, Oscient was gathering additional data on the market experience of gemifloxacin tablets to be included in the filing [&lt;ulink linkID="562079" linkType="Reference"&gt;562079&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Otitis media&lt;/subtitle&gt;In September 2008, phase III trials were underway in Korea [&lt;ulink linkID="946709" linkType="Reference"&gt;946709&lt;/ulink&gt;]. In February 2010, it was reported that a clinical program was conducted  in  hospitals in 194 patients with otitis media between 2006 and 2009. Gemifloxacin (320 mg, po) given  over seven days exhibited efficacy and was a shorter treatment period compared to conventional antibiotics [&lt;ulink linkID="1101450" linkType="Reference"&gt;1101450&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other data&lt;/subtitle&gt;In March 2005, data presented at the 10th Antibacterial Drug Discovery &amp;amp; Development Summit in San Diego, CA, noted incidence of  mild, self-resolving,  rash covering 40 to 50% of the body occurring at higher doses in young women (below 40-year-old) treated for more than 7 days. There was no Stevens-Johnson syndrome, angioedema, toxic necrolysis, or vasculitis [&lt;ulink linkID="593712" linkType="Reference"&gt;593712&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;Further data on gemifloxacin presented at the 40th ICAAC meeting were from a study of multidose pharmacokinetics and tolerability in elderly volunteers after a once-daily repeat administration of gemifloxacin (320 mg, po). These showed gemifloxacin to be well tolerated with no clinically important alterations in a range of biochemical or physiological parameters [&lt;ulink linkID="381887" linkType="reference"&gt;381887&lt;/ulink&gt;], [&lt;ulink linkID="383201" linkType="reference"&gt;383201&lt;/ulink&gt;], [&lt;ulink linkID="383202" linkType="reference"&gt;383202&lt;/ulink&gt;]. Gemifloxacin was also well tolerated in a study with healthy male Japanese and Caucasian volunteers, with similar pharmacokinetics displayed across both groups [&lt;ulink linkID="383199" linkType="reference"&gt;383199&lt;/ulink&gt;]. Gemifloxacin was judged to have no clinically relevant effect on QTc interval in studies involving a total of 119 subjects [&lt;ulink linkID="381894" linkType="reference"&gt;381894&lt;/ulink&gt;]. Furthermore, gemifloxacin was shown to be able to achieve high intracellular concentrations in vitro in human polymorphonuclear leukocytes, and it remained active in this intracellular compartment [&lt;ulink linkID="383203" linkType="reference"&gt;383203&lt;/ulink&gt;], [&lt;ulink linkID="383322" linkType="reference"&gt;383322&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;In July 2000, at the CPT Meeting in Florence, gemifloxacin was assessed at an oral dose of 320 mg daily in five phase III trials involving 1423 patients aged 16 to 92 suffering from various microbial infections. Population pharmacokinetics (PKs) were ascertained using a two compartment model with first-order absorption and elimination. PK modeling found that creatinine clearance and body weight were the only significant descriptors of central distribution volume and oral clearance. Compared to patients having normal renal function, patients with a creatinine clearance of 60 and 40 ml/min were predicted to exhibit 1.2- and 1.4-fold increases in AUC. The study suggested that doses of 320 mg were appropriate for patients with a creatinine clearance over 40 ml/min, while patients with reduced renal function should be administered doses of gemifloxacin of less than 320 mg [&lt;ulink linkID="377837" linkType="reference"&gt;377837&lt;/ulink&gt;], [&lt;ulink linkID="376915" linkType="reference"&gt;376915&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results presented at the 21st International Congress of Chemotherapy in 1999, revealed that no clinically significant drug interactions were observed following gemifloxacin administration [&lt;ulink linkID="331469" linkType="reference"&gt;331469&lt;/ulink&gt;], [&lt;ulink linkID="331779" linkType="reference"&gt;331779&lt;/ulink&gt;], [&lt;ulink linkID="331793" linkType="reference"&gt;331793&lt;/ulink&gt;], [&lt;ulink linkID="332013" linkType="reference"&gt;332013&lt;/ulink&gt;], [&lt;ulink linkID="332035" linkType="reference"&gt;332035&lt;/ulink&gt;]. A 7-day administration of gemifloxacin (320 mg, od) has low potential to cause mild photosensitivity similar to that observed with &lt;ulink linkID="44438" linkType="Drug"&gt;ciprofloxacin&lt;/ulink&gt; [&lt;ulink linkID="332440" linkType="reference"&gt;332440&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2004, preclinical data on gemifloxacin were presented at the Sixth SMi Superbugs &amp;amp; Superdrugs: A Focus on Antibacterials meeting in London, UK. Gemifloxacin demonstrated an MIC value of 0.015 microg/ml against wild type S aureus and IC50 values of  2.5 to 5 and 5 to 10 microM against S pneumoniae topoisomerase IV and DNA gyrase, respectively [&lt;ulink linkID="526511" linkType="reference"&gt;526511&lt;/ulink&gt;], [&lt;ulink linkID="526541" linkType="reference"&gt;526541&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2002, preclinical data were presented at the 42nd ICAAC meeting, San Diego, CA. Data from a study designed to determine whether gemifloxacin significantly modulated secretion of certain cytokines by LPS-stimulated human monocytes, and to investigate the cellular level at which the drug might interfere with cytokine synthesis, were presented. These findings indicated that gemifloxacin modulated the immune response by altering secretion of cytokines by human monocytes, and appeared to exert its inhibitory activity at the post-transcriptional level. No inhibitory effect of the antibiotic on the kinetics and extent of activation of NF-kB by LPS was demonstrated [&lt;ulink linkID="464630" linkType="reference"&gt;464630&lt;/ulink&gt;]. Results from several comparative studies involving gemifloxacin were also presented, including that from an assessment of the in vivo postantibiotic suppressive effect (PAE) of this drug in comparison to &lt;ulink linkID="44438" linkType="Drug"&gt;ciprofloxacin&lt;/ulink&gt; and &lt;ulink linkID="2867" linkType="Drug"&gt;trovafloxacin&lt;/ulink&gt; on MSSA, S pneumoniae pen-S and pen-R, E coli and K pneumoniae in a neutropenic mouse thigh model. Gemifloxacin demonstrated a long in vivo PAE, similar to trovafloxacin and significantly longer than ciprofloxacin for gram-positive strains [&lt;ulink linkID="464465" linkType="reference"&gt;464465&lt;/ulink&gt;]. In addition, gemifloxacin, and other quinolones showed promising activity in combination with imipenem against Burkholderia pseudomallei [&lt;ulink linkID="464646" linkType="reference"&gt;464646&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2002, preclinical data on gemifloxacin were presented at the Clinical Microbiology and Infectious Diseases 12th European Congress in Milan, Italy. Among the isolates tested, a group of highly resistant isolates with elevated MIC values to quinolones were also selected. Even for the most &lt;ulink linkID="44438" linkType="Drug"&gt;ciprofloxacin&lt;/ulink&gt;-resistant isolates, gemifloxacin MIC values were less than 2 mg/l [&lt;ulink linkID="450804" linkType="reference"&gt;450804&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2001, preclinical data on gemifloxacin were presented at the 41st ICAAC meeting in Chicago, IL. Gemifloxacin showed in vitro activity against a number of species including C pneumoniae [&lt;ulink linkID="421262" linkType="reference"&gt;421262&lt;/ulink&gt;] and S pneumoniae [&lt;ulink linkID="421263" linkType="reference"&gt;421263&lt;/ulink&gt;], [&lt;ulink linkID="421266" linkType="reference"&gt;421266&lt;/ulink&gt;]. Gemifloxacin also performed well against &lt;ulink linkID="44438" linkType="Drug"&gt;ciprofloxacin&lt;/ulink&gt;, ofloxacin, &lt;ulink linkID="3492" linkType="Drug"&gt;levofloxacin&lt;/ulink&gt;, &lt;ulink linkID="7017" linkType="Drug"&gt;gatifloxacin&lt;/ulink&gt;, &lt;ulink linkID="12978" linkType="Drug"&gt;moxifloxacin&lt;/ulink&gt;, imipenem and metronidazole in comparative studies against S pneumoniae [&lt;ulink linkID="421272" linkType="reference"&gt;421272&lt;/ulink&gt;], [&lt;ulink linkID="421275" linkType="reference"&gt;421275&lt;/ulink&gt;], [&lt;ulink linkID="421276" linkType="reference"&gt;421276&lt;/ulink&gt;], [&lt;ulink linkID="421277" linkType="reference"&gt;421277&lt;/ulink&gt;], [&lt;ulink linkID="421281" linkType="reference"&gt;421281&lt;/ulink&gt;]. Gemifloxacin showed 43% binding to rat serum proteins and produced a greater than 2.5 log10 reduction against two of five S pneumoniae strains with MICs of 0.5 microg/ml. Efficacy correlated with an AUC/MIC ratio of 25 for total drug [&lt;ulink linkID="421519" linkType="reference"&gt;421519&lt;/ulink&gt;]. In other studies, gemifloxacin was four- to eight-fold more active than ciprofloxacin against gram positive species with an MIC range of 0.002 to 0.06 mg/l [&lt;ulink linkID="421752" linkType="reference"&gt;421752&lt;/ulink&gt;], [&lt;ulink linkID="421753" linkType="reference"&gt;421753&lt;/ulink&gt;]. Similar data were presented in November 2004 at the 44th ICAAC meeting in Washington DC [&lt;ulink linkID="568718" linkType="Reference"&gt;568718&lt;/ulink&gt;], [&lt;ulink linkID="569068" linkType="Reference"&gt;569068&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2001, preclinical data on gemifloxacin were presented at the 11th European Congress of Clinical Microbiology and Infectious Diseases meeting in Istanbul, Turkey. Results predicted greater efficacy of gemifloxacin against H influenzae relative to &lt;ulink linkID="44438" linkType="Drug"&gt;ciprofloxacin&lt;/ulink&gt; [&lt;ulink linkID="416855" linkType="reference"&gt;416855&lt;/ulink&gt;]. Similar efficacy results were predicted in comparative studies with &lt;ulink linkID="3492" linkType="Drug"&gt;levofloxacin&lt;/ulink&gt;  [&lt;ulink linkID="416874" linkType="reference"&gt;416874&lt;/ulink&gt;]. Gemifloxacin exhibited comparable activity against difficult-to-treat nosocomial pathogens compared to commonly used antimicrobial agents [&lt;ulink linkID="416878" linkType="reference"&gt;416878&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In vitro data, also presented at 40th ICAAC meeting, showed gemifloxacin to have high activity against antibiotic-resistant Streptococcus pneumoniae, H influenzae and M catarrhalis [&lt;ulink linkID="381613" linkType="reference"&gt;381613&lt;/ulink&gt;], [&lt;ulink linkID="381614" linkType="reference"&gt;381614&lt;/ulink&gt;], [&lt;ulink linkID="381936" linkType="reference"&gt;381936&lt;/ulink&gt;], [&lt;ulink linkID="382663" linkType="reference"&gt;382663&lt;/ulink&gt;]. Comparison of the PAEs of gemifloxacin, &lt;ulink linkID="12978" linkType="Drug"&gt;moxifloxacin&lt;/ulink&gt;, &lt;ulink linkID="44438" linkType="Drug"&gt;ciprofloxacin&lt;/ulink&gt; and &lt;ulink linkID="3492" linkType="Drug"&gt;levofloxacin&lt;/ulink&gt; at fourfold MIC against clinical isolates of respiratory pathogens were made. All PAEs were comparable against S pneumoniae but, against the H influenzae and M catarrhalis isolates, gemifloxacin and levofloxacin had considerably longer PAEs than moxifloxacin and ciprofloxacin [&lt;ulink linkID="381614" linkType="reference"&gt;381614&lt;/ulink&gt;], [&lt;ulink linkID="381616" linkType="reference"&gt;381616&lt;/ulink&gt;]. In rats, gemifloxacin showed promising results as a treatment for experimental endocarditis [&lt;ulink linkID="382143" linkType="reference"&gt;382143&lt;/ulink&gt;] and RTI [&lt;ulink linkID="382144" linkType="reference"&gt;382144&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Other important data presented at 40th ICAAC meeting suggested that the primary target for gemifloxacin in H influenzae is DNA gyrase and that resistance development is associated with reduced sensitivity of this enzyme [&lt;ulink linkID="381876" linkType="reference"&gt;381876&lt;/ulink&gt;] while further presentations described the effectiveness in vitro of gemifloxacin against a cornucopia of bacterial isolates [&lt;ulink linkID="383278" linkType="reference"&gt;383278&lt;/ulink&gt;], [&lt;ulink linkID="383279" linkType="reference"&gt;383279&lt;/ulink&gt;], [&lt;ulink linkID="383280" linkType="reference"&gt;383280&lt;/ulink&gt;], [&lt;ulink linkID="383281" linkType="reference"&gt;383281&lt;/ulink&gt;], [&lt;ulink linkID="383282" linkType="reference"&gt;383282&lt;/ulink&gt;], [&lt;ulink linkID="383283" linkType="reference"&gt;383283&lt;/ulink&gt;], [&lt;ulink linkID="383286" linkType="reference"&gt;383286&lt;/ulink&gt;], [&lt;ulink linkID="383287" linkType="reference"&gt;383287&lt;/ulink&gt;], [&lt;ulink linkID="383289" linkType="reference"&gt;383289&lt;/ulink&gt;], [&lt;ulink linkID="383290" linkType="reference"&gt;383290&lt;/ulink&gt;], [&lt;ulink linkID="383292" linkType="reference"&gt;383292&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2000, at the 100th General Meeting of the American Society for Microbiology in Los Angeles, CA, gemifloxacin was shown to be the most active antimicrobial tested against penicillin- , macrolide- or gemifloxacin-resistant S pneumoniae. Results from the Alexander Project, an international resistance surveillance program, demonstrated that gemifloxacin had a more potent activity than &lt;ulink linkID="2587" linkType="Drug"&gt;azithromycin&lt;/ulink&gt;, &lt;ulink linkID="2829" linkType="Drug"&gt;clarithromycin&lt;/ulink&gt; and other fluoroquinolones, when tested against key respiratory tract infections and other common pathogens, including macrolide-resistant S pneumoniae and beta-lactamase positive Haemophilus influenzae [&lt;ulink linkID="369019" linkType="reference"&gt;369019&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In studies published in 2000, the in vitro activity of gemifloxacin against gram-negative bacteria containing plasmid pMG252 conferring resistance to quinolones was reported; MICs and MBCs of gemifloxacin against gram-negative bacteria increased several times when the strain contained pMG252 [&lt;ulink linkID="369213" linkType="reference"&gt;369213&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In data presented in September 1999, gemifloxacin's post antibiotic effect was shown to vary from 2.1 to 4.3 h against both penicillin-susceptible and penicillin-resistant strains of S pneumoniae. In comparison studies with other fluoroquinolones, such as &lt;ulink linkID="4439" linkType="Drug"&gt;sparfloxacin&lt;/ulink&gt; and &lt;ulink linkID="44438" linkType="Drug"&gt;ciprofloxacin&lt;/ulink&gt;, gemifloxacin demonstrated more potent activity against quinolone-sensitive S aureus (MIC90 = 0.03 microg/ml) and S epidermidis (MIC90 = 0.015 microg/ml). SB-265805 was also more potent than &lt;ulink linkID="2867" linkType="Drug"&gt;trovafloxacin&lt;/ulink&gt; against ciprofloxacin-resistant S aureus and S epidermidis and showed similar potency to trovafloxacin against quinolone-sensitive S aureus. The most striking activity of gemifloxacin was its potency against S pneumoniae (MIC90 = 0.25 microg/ml) compared to trovafloxacin (MIC90 = 4 microg/ml), sparfloxacin (MIC90 = 32 microg/ml) and ciprofloxacin (MIC90 = 64 microg/ml). Gemifloxacin also demonstrated good activity against Escherichia coli (MIC90 = 0.25 microg/ml) and Klebsiella pneumoniae (MIC90 = 0.5 micro/ml). Gemifloxacin demonstrated potent anti-gonoccocal activity against both quinolone-susceptible and quinolone-resistant strains of Neisseria gonorrhoeae. Against ciprofloxacin-resistant strains of N gonorrhoeae, gemifloxacin demonstrated equivalent activity to &lt;ulink linkID="2587" linkType="Drug"&gt;azithromycin&lt;/ulink&gt; (MIC90 = 0.12 microg/ml) [&lt;ulink linkID="342706" linkType="reference"&gt;342706&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;At the end of 1998, &lt;ulink linkID="19962" linkType="Company"&gt;SmithKline Beecham&lt;/ulink&gt; was evaluating a pediatric formulation in preclinical studies [&lt;ulink linkID="323259" linkType="reference"&gt;323259&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 2008, the FDA notified manufacturers of fluoroquinolone antimicrobial drugs, including gemifloxacin, that a boxed warning  concerning the increased risk of tendinitis and tendon rupture was necessary [&lt;ulink linkID="923602" linkType="Reference"&gt;923602&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Zhenkun Ma PhD, &lt;ulink linkType="Company" linkID="13601"&gt;Abbott Laboratories&lt;/ulink&gt;, IL, USA&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;11 June 1999&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Fluoroquinolones such as &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt; are potent broad-spectrum antibacterial agents, exerting their bactericidal effect by inhibiting type II bacterial DNA topoisomerase. They are active against a broad range of Gram-positive and Gram-negative pathogens and are widely used for the treatment of lower respiratory tract infections, skin and soft tissue infections, sexually transmitted diseases and urinary tract infections. However, the clinical application of current fluoroquinolones has been limited by their insufficient activity against many clinically important Gram-positive bacteria. The effectiveness of fluoroquinolones has also been challenged by the increasing prevalence of quinolone-resistant bacteria. &lt;ulink linkType="Drug" linkID="2867"&gt;Trovafloxacin&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="18767"&gt;Pfizer Inc&lt;/ulink&gt;), a fluoroquinolone introduced recently, exhibits improved antibacterial activity against Gram-positive bacteria and anaerobes. SB-265805 is one of several quinolones under clinical development to address the deficiencies of the current fluoroquinolones.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;SB-265805 is a fluoronaphthyridone derivative with a novel 4-(aminomethyl)-3-(methoxyimino)pyrrolidine moiety at the 7-position. The pyrrolidine side chain was synthesized in eight steps from ethyl glycine and was then coupled to the known naphthyridone core in good yield [&lt;ulink linkType="reference" linkID="270380"&gt;270380&lt;/ulink&gt;]. Structure-activity relationship studies indicated that the methyloxime and aminomethyl groups of the pyrrolidine have a synergistic effect on the antibacterial activity [&lt;ulink linkType="reference" linkID="307258"&gt;307258&lt;/ulink&gt;]. The O-alkyl substituents of the oxime are also important to the antibacterial spectrum and activity. As the alkyl group increases in size, the Gram-positive activity becomes enhanced, while the Gram-negative activity decreases [&lt;ulink linkType="reference" linkID="307256"&gt;307256&lt;/ulink&gt;]. SB-265805 possesses a balanced activity against both Gram-positive and Gram-negative bacteria. It is worth noting that SB-265805 is a racemic mixture containing two enantiomers. The synthesis and comprehensive evaluations of the antibacterial and pharmacological profiles of these pure enantiomers have not been reported.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;SB-265805 displays a broad antibacterial spectrum covering both Gram-positive and Gram-negative bacteria. It is more active than &lt;ulink linkType="Drug" linkID="5620"&gt;grepafloxacin&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="18717"&gt;Otsuka Pharmaceutical&lt;/ulink&gt; Co), &lt;ulink linkType="Drug" linkID="4439"&gt;sparfloxacin&lt;/ulink&gt; (Dainippon Pharmaceutical Co), &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt; and ofloxacin against Gram-positive cocci [&lt;ulink linkType="reference" linkID="307236"&gt;307236&lt;/ulink&gt;]. It is as potent as &lt;ulink linkType="Drug" linkID="2867"&gt;trovafloxacin&lt;/ulink&gt; against methicillin-susceptible S aureus, methicillin-resistant S aureus, methicillin-susceptible S epidermidis and methicillin-resistant S epidermidis. SB-265805 exhibits better activity against penicillin-susceptible, penicillin-resistant, and &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt;-resistant S pneumoniae than all reference quinolones tested, including &lt;ulink linkType="Drug" linkID="2867"&gt;trovafloxacin&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="307231"&gt;307231&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="307239"&gt;307239&lt;/ulink&gt;]. Against Gram-negative bacteria, SB-265805 is as active as other reference quinolones including &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="307236"&gt;307236&lt;/ulink&gt;]. SB-265805 is highly active against common respiratory tract pathogens, including strains resistant to macrolides, beta-lactams and other quinolones [&lt;ulink linkType="reference" linkID="307239"&gt;307239&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="307264"&gt;307264&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="307283"&gt;307283&lt;/ulink&gt;]. Like many other fluoroquinolones, SB-265805 is rapidly accumulated by human macrophages in vitro and is active against facultative intracellular pathogens [&lt;ulink linkType="reference" linkID="307268"&gt;307268&lt;/ulink&gt;]. Compared to &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt;, SB-265805 shows improved selectivity between bacterial DNA gyrase and human topoisomerase II [&lt;ulink linkType="reference" linkID="307233"&gt;307233&lt;/ulink&gt;]. SB-265805 also displays rapid bactericidal activity [&lt;ulink linkType="reference" linkID="307235"&gt;307235&lt;/ulink&gt;] and desired post-antibiotic effects [&lt;ulink linkType="reference" linkID="307232"&gt;307232&lt;/ulink&gt;], comparable to that of &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;SB-265805 demonstrates excellent in vivo efficacy against systemic infections in experimental animal models [&lt;ulink linkType="reference" linkID="270380"&gt;270380&lt;/ulink&gt;]. It is more efficacious than &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt; against Gram-positive infections and about equally efficacious as &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt; against Gram-negative infections [&lt;ulink linkType="reference" linkID="263161"&gt;263161&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="221013"&gt;221013&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;SB-265805 exhibits a favorable pharmacokinetic profile in rats and dogs after oral administration [&lt;ulink linkType="reference" linkID="270380"&gt;270380&lt;/ulink&gt;]. The drug was 95% and 71% bioavailable in rats and dogs as compared to 45% and 75% for &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt;. Higher plasma concentration was achieved in rats at a single dose of 20 mg/kg (Cmax 2.44 microg/ml for SB-265805 versus 0.90 microg/ml for &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt;) and in dogs at 4 mg/kg (1.34 microg/ml versus 0.91 microg/ml). The plasma elimination half-life for SB-265805 was also longer than that of &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt; (2.33 h versus 1.87 h in rats and 5.12 h versus 1.70 h in dogs). Human pharmacokinetic data are not currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;SB-265805 did not induce convulsions in mice when co-administered with 4-biphenylacetic acid at 100 mg/kg oral dose. The dose that induced convulsions in 50% of animals by intracerebral ventricular injection was 169 nM as compared to 35 nM for &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt; and 105 nM for ofloxacin [&lt;ulink linkType="reference" linkID="221013"&gt;221013&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="263161"&gt;263161&lt;/ulink&gt;]. No other toxicity data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;SB-265805 was well-tolerated during the initial single and multiple dose studies in the UK by LG Chemicals [&lt;ulink linkType="reference" linkID="217876"&gt;217876&lt;/ulink&gt;]. Phase I studies indicated that the compound is well-tolerated and has a low phototoxicity potential. Once daily dosing was predicted to be effective [&lt;ulink linkType="reference" linkID="299916"&gt;299916&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In 1998, &lt;ulink linkType="Company" linkID="19962"&gt;SmithKline Beecham&lt;/ulink&gt; commenced phase II trails in the UK and the US for the treatment of respiratory tract infections and other bacterial infections [&lt;ulink linkType="reference" linkID="277513"&gt;277513&lt;/ulink&gt;]. The same studies were initiated in South Korea by LG Chemicals. The tolerability and efficacy were further confirmed [&lt;ulink linkType="reference" linkID="299916"&gt;299916&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;Phase III studies are underway but no data are currently available. &lt;ulink linkType="Company" linkID="19962"&gt;SmithKline Beecham&lt;/ulink&gt; plans to file for US and European approval by the first quarter of year 2000 [&lt;ulink linkType="reference" linkID="284490"&gt;284490&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and Contraindications&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;New safe and effective antibacterial agents are in great demand due to increased beta-lactam and macrolide resistance among the common respiratory tract pathogens. Quinolones are thus becoming widely accepted as first-line therapy for the treatment of respiratory tract infections in order to address the drug resistance problems. This transition is further infused by the introduction of newer quinolones with improved Gram-positive activity and better safety profiles. Following the introductions of &lt;ulink linkType="Drug" linkID="3492"&gt;levofloxacin&lt;/ulink&gt; and travofloxacin, SB-265805 is one of several new quinolones in clinical development for the treatment of respiratory tract infections. The potential market of SB-265805 will be shaped by several factors: coverage against key respiratory pathogens, activity against drug resistance, convenience of dose regimen, cost of therapy, and more importantly, safety and tolerability. SB-265805 is a broad-spectrum agent with good coverage against all the common respiratory pathogens, including those resistant to other quinolones. Its activity against S pneumoniae, a key respiratory pathogen, is particularly impressive. Although no human pharmacokinetic data are available, the limited preclinical data suggest that this compound has a favorable pharmacokinetic profile and has the potential to be a once daily drug. However, SB-265805, as well as other quinolones, has to compete with the safe, well-tolerated traditional respiratory tract antibiotics. The safety and tolerability will be the key issues for their success. The clinical data for SB-265805 are not currently available for the accurate assessment of its safety and tolerability profiles.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2013-04-01T00:00:00.000Z</StatusDate><Source id="1443788" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2013-04-01T00:00:00.000Z</StatusDate><Source id="1443788" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1068473">Vansen Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>2012-03-07T00:00:00.000Z</StatusDate><Source id="1269523" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>2006-10-05T00:00:00.000Z</StatusDate><Source id="728581" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2015-04-23T00:00:00.000Z</StatusDate><Source id="1653472" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13708">Ache Laboratorios Farmaceuticos SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2017-11-08T00:00:00.000Z</StatusDate><Source id="2120389" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate>2015-04-23T00:00:00.000Z</StatusDate><Source id="1653472" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13708">Ache Laboratorios Farmaceuticos SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>2017-11-08T00:00:00.000Z</StatusDate><Source id="2120389" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13708">Ache Laboratorios Farmaceuticos SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1061">Sinusitis</Indication><StatusDate>2017-11-08T00:00:00.000Z</StatusDate><Source id="2120389" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1068473">Vansen Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2012-03-07T00:00:00.000Z</StatusDate><Source id="1269523" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate>2013-04-01T00:00:00.000Z</StatusDate><Source id="1443788" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2013-11-08T00:00:00.000Z</StatusDate><Source id="1497639" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2013-11-08T00:00:00.000Z</StatusDate><Source id="1497639" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="40">Bacterial infection</Indication><StatusDate>2002-04-16T00:00:00.000Z</StatusDate><Source id="447913" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2002-04-16T00:00:00.000Z</StatusDate><Source id="447913" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2009-02-19T00:00:00.000Z</StatusDate><Source id="1471781" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2002-04-16T00:00:00.000Z</StatusDate><Source id="447913" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="360">Pneumonia</Indication><StatusDate>2002-04-16T00:00:00.000Z</StatusDate><Source id="447913" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1061">Sinusitis</Indication><StatusDate>2002-04-16T00:00:00.000Z</StatusDate><Source id="447913" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2002-04-16T00:00:00.000Z</StatusDate><Source id="447913" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2002-04-16T00:00:00.000Z</StatusDate><Source id="447913" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30124">aRigen Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30124">aRigen Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="IN">India</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15523">Oscient Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1061">Sinusitis</Indication><StatusDate>2011-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1043326">Chiesi USA Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>2012-03-07T00:00:00.000Z</StatusDate><Source id="1269523" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2002-10-22T00:00:00.000Z</StatusDate><Source id="467547" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2013-04-01T00:00:00.000Z</StatusDate><Source id="1443788" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate>2013-04-01T00:00:00.000Z</StatusDate><Source id="1443788" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2002-10-22T00:00:00.000Z</StatusDate><Source id="467547" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062392">Merus Labs International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2012-03-07T00:00:00.000Z</StatusDate><Source id="1269523" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15523">Oscient Pharmaceuticals Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2006-08-11T00:00:00.000Z</StatusDate><Source id="683546" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15523">Oscient Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2009-09-09T00:00:00.000Z</StatusDate><Source id="1054480" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1043326">Chiesi USA Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2012-03-07T00:00:00.000Z</StatusDate><Source id="1269523" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2002-10-22T00:00:00.000Z</StatusDate><Source id="467547" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062392">Merus Labs International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>2012-03-07T00:00:00.000Z</StatusDate><Source id="1269523" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2002-10-22T00:00:00.000Z</StatusDate><Source id="467547" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2013-04-01T00:00:00.000Z</StatusDate><Source id="1443788" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15523">Oscient Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>2009-09-09T00:00:00.000Z</StatusDate><Source id="1054480" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15523">Oscient Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1061">Sinusitis</Indication><StatusDate>2005-11-21T00:00:00.000Z</StatusDate><Source id="636322" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15523">Oscient Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>2004-09-09T00:00:00.000Z</StatusDate><Source id="558496" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2006-10-05T00:00:00.000Z</StatusDate><Source id="728581" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30124">aRigen Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2006-02-28T00:00:00.000Z</StatusDate><Source id="683995" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30124">aRigen Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2005-05-19T00:00:00.000Z</StatusDate><Source id="602447" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2006-02-28T00:00:00.000Z</StatusDate><Source id="683995" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="IN">India</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2006-02-28T00:00:00.000Z</StatusDate><Source id="683995" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1043326">Chiesi USA Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>2009-09-09T00:00:00.000Z</StatusDate><Source id="1054480" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1043326">Chiesi USA Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2009-09-09T00:00:00.000Z</StatusDate><Source id="1054480" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2006-02-28T00:00:00.000Z</StatusDate><Source id="683995" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate>2010-03-01T00:00:00.000Z</StatusDate><Source id="1101450" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2003-01-01T00:00:00.000Z</StatusDate><Source id="1101360" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2007-03-02T00:00:00.000Z</StatusDate><Source id="770159" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22235">LG Chem Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2002-04-16T00:00:00.000Z</StatusDate><Source id="447913" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22235">LG Chem Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2002-04-16T00:00:00.000Z</StatusDate><Source id="447913" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22235">LG Chem Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2002-04-16T00:00:00.000Z</StatusDate><Source id="447913" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22235">LG Chem Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2002-04-16T00:00:00.000Z</StatusDate><Source id="447913" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22235">LG Chem Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>1998-07-01T00:00:00.000Z</StatusDate><Source id="311119" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22235">LG Chem Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>1995-10-09T00:00:00.000Z</StatusDate><Source id="188621" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1061">Sinusitis</Indication><StatusDate>1999-12-01T00:00:00.000Z</StatusDate><Source id="323259" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>1999-12-01T00:00:00.000Z</StatusDate><Source id="391615" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>1998-02-13T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>1997-01-01T00:00:00.000Z</StatusDate><Source id="246002" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2015-04-23T00:00:00.000Z</StatusDate><Source id="1653472" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate>2015-04-23T00:00:00.000Z</StatusDate><Source id="1653472" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13708">Ache Laboratorios Farmaceuticos SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13708">Ache Laboratorios Farmaceuticos SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1061">Sinusitis</Indication><StatusDate>2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13708">Ache Laboratorios Farmaceuticos SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28023">Genesoft Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2002-10-22T00:00:00.000Z</StatusDate><Source id="467547" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28023">Genesoft Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2003-04-04T00:00:00.000Z</StatusDate><Source id="484780" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28023">Genesoft Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2002-10-22T00:00:00.000Z</StatusDate><Source id="467547" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24151">SmithKline Beecham Pharmaceuticals [US]</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1061">Sinusitis</Indication><StatusDate>1999-12-16T00:00:00.000Z</StatusDate><Source id="350783" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24151">SmithKline Beecham Pharmaceuticals [US]</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2000-10-05T00:00:00.000Z</StatusDate><Source id="384751" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24151">SmithKline Beecham Pharmaceuticals [US]</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>1999-12-16T00:00:00.000Z</StatusDate><Source id="350783" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24151">SmithKline Beecham Pharmaceuticals [US]</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>1999-12-16T00:00:00.000Z</StatusDate><Source id="350783" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24151">SmithKline Beecham Pharmaceuticals [US]</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>1999-12-16T00:00:00.000Z</StatusDate><Source id="350783" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24151">SmithKline Beecham Pharmaceuticals [US]</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>1998-04-01T00:00:00.000Z</StatusDate><Source id="285766" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24151">SmithKline Beecham Pharmaceuticals [US]</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>1998-04-01T00:00:00.000Z</StatusDate><Source id="285766" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2001-02-27T00:00:00.000Z</StatusDate><Source id="399771" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2001-02-27T00:00:00.000Z</StatusDate><Source id="399771" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2001-02-27T00:00:00.000Z</StatusDate><Source id="399771" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2001-02-27T00:00:00.000Z</StatusDate><Source id="399771" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28023">Genesoft Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2004-03-11T00:00:00.000Z</StatusDate><Source id="527068" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2002-10-22T00:00:00.000Z</StatusDate><Source id="504415" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2002-10-22T00:00:00.000Z</StatusDate><Source id="504415" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2002-10-22T00:00:00.000Z</StatusDate><Source id="504415" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2002-12-31T00:00:00.000Z</StatusDate><Source id="490551" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15523">Oscient Pharmaceuticals Corp</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2006-08-01T00:00:00.000Z</StatusDate><Source id="681390" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15523">Oscient Pharmaceuticals Corp</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>2006-08-01T00:00:00.000Z</StatusDate><Source id="681390" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15523">Oscient Pharmaceuticals Corp</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1061">Sinusitis</Indication><StatusDate>2006-08-01T00:00:00.000Z</StatusDate><Source id="681390" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2006-08-11T00:00:00.000Z</StatusDate><Source id="683546" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15523">Oscient Pharmaceuticals Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2004-09-09T00:00:00.000Z</StatusDate><Source id="527068" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15523">Oscient Pharmaceuticals Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>2005-02-28T00:00:00.000Z</StatusDate><Source id="587377" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="X5">Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="360">Pneumonia</Indication><StatusDate>2008-05-07T00:00:00.000Z</StatusDate><Source id="903511" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="X5">Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1061">Sinusitis</Indication><StatusDate>2008-05-07T00:00:00.000Z</StatusDate><Source id="903511" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate>2002-12-26T00:00:00.000Z</StatusDate><Source id="1101360" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="946709" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate>2010-02-01T00:00:00.000Z</StatusDate><Source id="1101450" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00623"><Name>DNA gyrase</Name><SwissprotNumbers><Swissprot>O08399</Swissprot><Swissprot>O29720</Swissprot><Swissprot>O33149</Swissprot><Swissprot>O33367</Swissprot><Swissprot>O33926</Swissprot><Swissprot>O50627</Swissprot><Swissprot>O50628</Swissprot><Swissprot>O51396</Swissprot><Swissprot>O51859</Swissprot><Swissprot>O67108</Swissprot><Swissprot>O67137</Swissprot><Swissprot>O83051</Swissprot><Swissprot>O84192</Swissprot><Swissprot>O84193</Swissprot><Swissprot>O87545</Swissprot><Swissprot>O87667</Swissprot><Swissprot>P05652</Swissprot><Swissprot>P05653</Swissprot><Swissprot>P0A0K7</Swissprot><Swissprot>P0A0K8</Swissprot><Swissprot>P0A2I3</Swissprot><Swissprot>P0A2I4</Swissprot><Swissprot>P0A4L9</Swissprot><Swissprot>P0A4M0</Swissprot><Swissprot>P0AES4</Swissprot><Swissprot>P0AES6</Swissprot><Swissprot>P0C0Q9</Swissprot><Swissprot>P0C0R0</Swissprot><Swissprot>P0C559</Swissprot><Swissprot>P0C5C5</Swissprot><Swissprot>P13364</Swissprot><Swissprot>P14829</Swissprot><Swissprot>P20831</Swissprot><Swissprot>P21557</Swissprot><Swissprot>P21558</Swissprot><Swissprot>P22118</Swissprot><Swissprot>P22446</Swissprot><Swissprot>P22447</Swissprot><Swissprot>P22840</Swissprot><Swissprot>P29435</Swissprot><Swissprot>P31860</Swissprot><Swissprot>P33769</Swissprot><Swissprot>P34030</Swissprot><Swissprot>P34031</Swissprot><Swissprot>P35810</Swissprot><Swissprot>P35885</Swissprot><Swissprot>P35886</Swissprot><Swissprot>P37411</Swissprot><Swissprot>P41080</Swissprot><Swissprot>P41513</Swissprot><Swissprot>P43053</Swissprot><Swissprot>P43700</Swissprot><Swissprot>P43701</Swissprot><Swissprot>P47235</Swissprot><Swissprot>P47249</Swissprot><Swissprot>P47250</Swissprot><Swissprot>P47719</Swissprot><Swissprot>P47720</Swissprot><Swissprot>P48354</Swissprot><Swissprot>P48369</Swissprot><Swissprot>P48370</Swissprot><Swissprot>P48371</Swissprot><Swissprot>P48372</Swissprot><Swissprot>P50028</Swissprot><Swissprot>P50071</Swissprot><Swissprot>P50074</Swissprot><Swissprot>P50075</Swissprot><Swissprot>P55992</Swissprot><Swissprot>P57126</Swissprot><Swissprot>P57277</Swissprot><Swissprot>P66936</Swissprot><Swissprot>P66937</Swissprot><Swissprot>P72065</Swissprot><Swissprot>P72524</Swissprot><Swissprot>P77966</Swissprot><Swissprot>P77993</Swissprot><Swissprot>P94281</Swissprot><Swissprot>P94604</Swissprot><Swissprot>P94605</Swissprot><Swissprot>Q03470</Swissprot><Swissprot>Q43907</Swissprot><Swissprot>Q43947</Swissprot><Swissprot>Q44065</Swissprot><Swissprot>Q44080</Swissprot><Swissprot>Q44081</Swissprot><Swissprot>Q44088</Swissprot><Swissprot>Q44270</Swissprot><Swissprot>Q44271</Swissprot><Swissprot>Q44272</Swissprot><Swissprot>Q44273</Swissprot><Swissprot>Q44274</Swissprot><Swissprot>Q44275</Swissprot><Swissprot>Q44276</Swissprot><Swissprot>Q44277</Swissprot><Swissprot>Q44278</Swissprot><Swissprot>Q49166</Swissprot><Swissprot>Q49467</Swissprot><Swissprot>Q49608</Swissprot><Swissprot>Q55738</Swissprot><Swissprot>Q57532</Swissprot><Swissprot>Q59533</Swissprot><Swissprot>Q5HJZ0</Swissprot><Swissprot>Q5HJZ1</Swissprot><Swissprot>Q5HK03</Swissprot><Swissprot>Q5HK04</Swissprot><Swissprot>Q5XC58</Swissprot><Swissprot>Q5XD05</Swissprot><Swissprot>Q6GD84</Swissprot><Swissprot>Q6GD85</Swissprot><Swissprot>Q6GKT9</Swissprot><Swissprot>Q6GKU0</Swissprot><Swissprot>Q89AS3</Swissprot><Swissprot>Q89B37</Swissprot><Swissprot>Q8CQK4</Swissprot><Swissprot>Q8DPM2</Swissprot><Swissprot>Q8K7H2</Swissprot><Swissprot>Q8K840</Swissprot><Swissprot>Q8K9W2</Swissprot><Swissprot>Q8NKW8</Swissprot><Swissprot>Q8P116</Swissprot><Swissprot>Q8P1M4</Swissprot><Swissprot>Q92H87</Swissprot><Swissprot>Q92IZ6</Swissprot><Swissprot>Q932M0</Swissprot><Swissprot>Q99XG5</Swissprot><Swissprot>Q9A0L0</Swissprot><Swissprot>Q9FAX1</Swissprot><Swissprot>Q9FAX2</Swissprot><Swissprot>Q9KVX3</Swissprot><Swissprot>Q9L7L3</Swissprot><Swissprot>Q9L7Q5</Swissprot><Swissprot>Q9LCK0</Swissprot><Swissprot>Q9LCK1</Swissprot><Swissprot>Q9PKK3</Swissprot><Swissprot>Q9PKK4</Swissprot><Swissprot>Q9PR63</Swissprot><Swissprot>Q9X3Y3</Swissprot><Swissprot>Q9X3Y5</Swissprot><Swissprot>Q9X3Y6</Swissprot><Swissprot>Q9Z8R3</Swissprot><Swissprot>Q9Z8R4</Swissprot><Swissprot>Q9ZAQ6</Swissprot><Swissprot>Q9ZCX2</Swissprot><Swissprot>Q9ZFK1</Swissprot><Swissprot>Q9ZLD9</Swissprot><Swissprot>Q9ZLX3</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1068473">Vansen Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="13601">Abbott Laboratories</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15381">Chiesi Farmaceutici SpA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="15523">Oscient Pharmaceuticals Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18053">The Menarini Group</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22235">LG Chem Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="28724">Norgine BV</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="30124">aRigen Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>6</CountActive><CountInactive>1</CountInactive><CountTotal>7</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CO/N=C/1\CN(CC1CN)c2c(cc3c(=O)c(cn(c3n2)C4CC4)C(=O)O)F</Smiles><Smiles>CO/N=C/1\CN(CC1CN)c2c(cc3c(=O)c(cn(c3n2)C4CC4)C(=O)O)F.CS(=O)(=O)O</Smiles></StructureSmiles><Deals><Deal id="107883" title="aRigen to commercialize LGLS's gemifloxacin in Japan"/><Deal id="109154" title="Abbott Canada to commercialize Oscient Pharmaceuticals' gemifloxacin for AECB in Canada"/><Deal id="112588" title="Menarini to market Oscient's Factive in Europe"/><Deal id="118640" title="SmithKline Beecham to develop and commercialize LG Chemical's LB20304a outside Korea"/><Deal id="118645" title="Pfizer to market Oscient's Factive in Mexico"/><Deal id="127157" title="Cornerstone Therapeutics to acquire Oscient's Factive assets "/><Deal id="138375" title="Merus Labs to market Cornerstone's Factive and Spectracef in North America        "/><Deal id="138379" title="Vansen Pharma to market Merus Labs' Factive in North America      "/><Deal id="145595" title="Ildong to market LG Life Sciences' Factive in Korea "/><Deal id="162896" title="GeneSoft to acquire North American and European rights to LG Chemicals' gemifloxacin  "/><Deal id="247671" title="SB Pharmaco to supply LG Life Sciences' gemifloxacin"/></Deals><PatentFamilies><PatentFamily id="107711" number="WO-2006134608" title="Gemifloxacin process and polymorphs"/><PatentFamily id="1096737" number="US-20020082275" title="Methods of use of gemifloxacin compounds against fluoroquinolone resistant streptococcus pneumoniae bacteria"/><PatentFamily id="1139454" number="WO-00218336" title="Novel Process For Preparing 3-Aminomethyl-4-Z-Methoxyiminopyrrolidine"/><PatentFamily id="1170478" number="US-20010049378" title="Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria"/><PatentFamily id="1208388" number="WO-00017199" title="Process for the production of a naphthyridine carboxylic acid derivative (methanesulfonate sesquihydrate)"/><PatentFamily id="1258925" number="EP-01408034" title="Use of quinolone and quinolizinone derivatives as chemotherapeutic agents"/><PatentFamily id="1289286" number="GB-02400033" title="Use of fluoroquinolone antibiotics for the treatment of Q fever"/><PatentFamily id="1314024" number="WO-00115695" title="Methods of use of fluoroquinolone compounds against bacteria"/><PatentFamily id="1314657" number="EP-01000931" title="Process For Producing An N-Alkoxycarbonyl-N-Cyanoethyl Amino Acid Alkyl Ester"/><PatentFamily id="1314697" number="WO-00168649" title="Novel process for the preparation of a quinoline carboxylic acid derivative having a 7-(4-aminomethyl-3-oxime)pyrrolidine substituent"/><PatentFamily id="1318519" number="WO-2009104045" title="Ophthalmic gemifloxacin compositions for the treatment of ocular infections"/><PatentFamily id="1413043" number="IN-200701212" title="Preparation of gemifloxacin pivalate"/><PatentFamily id="1463267" number="EP-00688772" title="Novel quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3 -oxime) pyrrolidine substituents and processes for their preparation."/><PatentFamily id="1469876" number="KR-00491479" title="Process for drying and humidifying gemifloxacin mesylate"/><PatentFamily id="1489597" number="US-06803376" title="Method of use of quinolone compounds against pneumococcal and haemophilus bacteria"/><PatentFamily id="1779582" number="WO-03045390" title="A method of treating bacterial infections using gemifloxacin or a salt thereof and a beta -lactam antibiotic"/><PatentFamily id="1831199" number="WO-00145679" title="Use of chemotherapeutic agents"/><PatentFamily id="1910252" number="US-06331550" title="Methods of use of quinolone compounds against anaerobic pathogenic bacteria."/><PatentFamily id="2120724" number="EP-02143422" title="Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections"/><PatentFamily id="2130345" number="CN-101830921" title="Method for exciting 7-halogen of new fluoroquinoline-3-carboxylic acid and application thereof to condensation with sec-amine to form side chain"/><PatentFamily id="2181646" number="WO-2008053324" title="An improved process for the preparation of gemifloxacin mesylate"/><PatentFamily id="2206527" number="US-06340689" title="Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria."/><PatentFamily id="2227346" number="AR-00022098" title="Use of quinolone antibiotics, especially a gemifloxacin compound, for the manufacture of a medicament against bacterial infection."/><PatentFamily id="2227439" number="EP-02491920" title="Effervescent tablet, sachet and dry syrup of gemifloxacin"/><PatentFamily id="2244250" number="WO-09944991" title="Process for preparing a protected 4-aminomethyl-pyrrolidin-3-one."/><PatentFamily id="2297423" number="WO-03045389" title="A method of treating bacterial infections using gemifloxacin or a salt thereof and a carbapenem antibacterial agent"/><PatentFamily id="2301087" number="WO-2011037433" title="Use of a quinolone derivative containing 7-(4-aminomethyl-3-oxime)pyrrolidine group that is capable of inducing granulocyte colony stimulating factor for treatment of neutropenia and recovery of hematopoiesis"/><PatentFamily id="2348894" number="KR-2011030824" title="The eye drops for the prevention of the ocular infection or the treatment including the gemifloxacin"/><PatentFamily id="2617688" number="WO-2013157018" title="A process for the preparation of the core structure in quinolone and napthyridone class of antibiotics"/><PatentFamily id="2666167" number="WO-2014012090" title="Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof"/><PatentFamily id="271720" number="WO-00121176" title="Methods of use of fluoroquinolone compounds against bacteria"/><PatentFamily id="2963422" number="CN-104693088" title="A method for preparing gemifloxacin side chain"/><PatentFamily id="306156" number="IN-200502226" title="Novel salt of gemifloxacin"/><PatentFamily id="3197271" number="CN-105585518" title="A method for preparing intermediate of gemifloxacin"/><PatentFamily id="337843" number="WO-00118002" title="Process for production of naphthyridine-3-carboxylic acid derivatives"/><PatentFamily id="358225" number="WO-2004017925" title="Methods and reagents for preventing bacteremias"/><PatentFamily id="4008184" number="CN-107823204" title="A new use of gemifloxacin"/><PatentFamily id="433446" number="WO-03011450" title="Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof"/><PatentFamily id="493670" number="WO-00100209" title="Methods of use of fluoroquinolone compounds against bacteria"/><PatentFamily id="522920" number="WO-2012013850" title="Compound for treating neurodegenerative diseases, cognitive deficiencies and/or dementia"/><PatentFamily id="528819" number="IN-200701944" title="Synthesis of gemifloxacin"/><PatentFamily id="551571" number="WO-2006134431" title="Formate salt of gemifloxacin"/><PatentFamily id="577975" number="US-06262071" title="Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria."/><PatentFamily id="614733" number="WO-09842705" title="Salt of naphthyridine carboxylic acid derivative."/><PatentFamily id="65385" number="WO-2005040164" title="Process for preparing 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid"/><PatentFamily id="726806" number="WO-03087100" title="Process for preparing acid salts of gemifloxacin"/><PatentFamily id="740111" number="CN-101899044" title="Method for synthesizing gemifloxacin primary ring compound"/><PatentFamily id="750831" number="RU-02453347" title="Method of treating chronic infectious urethritis complicated by prostatitis"/><PatentFamily id="769427" number="US-20020137751" title="Method of treatment"/><PatentFamily id="787970" number="WO-2010001408" title="Novel polymorphic forms of gemifloxacin mesylate"/><PatentFamily id="810344" number="WO-2007064077" title="A process for preparing beta-ketoester compounds"/><PatentFamily id="874055" number="US-20020086868" title="Methods of use of gemifloxacin compounds against fluoroquinolone resistant streptococcus pneumoniae bacteria"/><PatentFamily id="929190" number="WO-00117961" title="Intermediates for the production of quinolone carboxylic acid derivatives"/><PatentFamily id="991122" number="WO-00238156" title="Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria"/><PatentFamily id="992582" number="WO-2004092129" title="New process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>14</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vansen Pharma Inc" id="1068473"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="LG Corp" id="1080494"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chiesi Farmaceutici SpA" id="15381"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Oscient Pharmaceuticals Corp" id="15523"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Menarini Group" id="18053"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tokuyama Soda KK" id="20402"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="LG Chem Ltd" id="22235"/><CountAsOwner>23</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>23</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tokuyama Corp" id="24882"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"/><CountAsOwner>16</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>17</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Norgine BV" id="28724"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universita Degli Studi di Genova" id="29077"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Heiko Hospital" id="DOL1000043"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hospital Britanico (Buenos Aires)" id="DOL1000046"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institute for Biomedical and Pharmaceutical Research" id="DOL1000056"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laiko General Hospital" id="DOL1000063"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sismanoglio General Hospital" id="DOL1000115"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universitat Duisburg Essen" id="DOL1000138"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Gregorio Maranon" id="DOL1000143"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>